Literature DB >> 21907639

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic.

Amanda L Griffiths1, Danielle F Wurzel, Phil J Robinson, Rosemary Carzino, John Massie.   

Abstract

AIM: To evaluate changes in prevalence of an epidemic strain of Pseudomonas aeruginosa (AES-1, Australian epidemic strain, type 1) in a paediatric cystic fibrosis (CF) centre practising cohort segregation, to describe the patients' clinical characteristics at acquisition and observe mortality rates.
METHODS: Cohort segregation was introduced in our paediatric CF clinic January 2000. The prevalence of AES-1 was analysed in 1999, 2002 and 2007. Age at acquisition, lung function, presence of bronchiectasis, hospitalisations, prior P. aeruginosa infection and mortality rates were collected. AES-1 infection was determined by pulse-field-gel-electrophoresis (PFGE) on airway specimen cultures taken three monthly.
RESULTS: The prevalence of AES-1 declined from 21% in 1999 to 14% in 2002 (risk difference 7% (95% CI 1,13) p=0.0256) and to 6% in 2007 (risk difference 8% (95% CI 3,13) p=0.0018). New acquisitions after the introduction of cohort segregation were uncommon (10 by 2002 and another 7 by 2007) with a declining incidence of 3.3 cases/year (1999 to 2002) compared to 1.4 cases/year (2002 to 2007). Twenty-two of 32 (69%) deaths between 1999 and 2007 occurred in patients infected with AES-1.
CONCLUSION: Cohort segregation has been associated with reductions in the prevalence of AES-1 in our CF clinic. Mortality was higher in patients infected with AES-1 than other organisms.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21907639     DOI: 10.1016/j.jcf.2011.08.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  5 in total

Review 1.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

2.  Incidence and prevalence of common respiratory pathogens before and after implementation of the Cystic Fibrosis Foundation Infection Prevention and Control Guideline.

Authors:  Christy Kim; Elizabeth delaRiva-Velasco; Arvind Budhram; Folashade Farri; Daniel Krich; Sheila S Nolan; Suzette Gjonaj; Lisa Paul; Allen J Dozor; John J Welter
Journal:  J Infect Prev       Date:  2019-09-25

3.  Homogentisate 1-2-Dioxygenase Downregulation in the Chronic Persistence of Pseudomonas aeruginosa Australian Epidemic Strain-1 in the CF Lung.

Authors:  Christopher J Harmer; Matthew Wynn; Rachel Pinto; Stuart Cordwell; Barbara R Rose; Colin Harbour; James A Triccas; Jim Manos
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

4.  The Effect of Strict Segregation on Pseudomonas aeruginosa in Cystic Fibrosis Patients.

Authors:  Rosa van Mansfeld; Angelica de Vrankrijker; Roland Brimicombe; Harry Heijerman; Ferdinand Teding van Berkhout; Cristian Spitoni; Sanne Grave; Cornelis van der Ent; Tom Wolfs; Rob Willems; Marc Bonten
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

Review 5.  Risk of Bacterial Transmission in Bronchiectasis Outpatient Clinics.

Authors:  Philip Mitchelmore; Catherine Wilson; David Hettle
Journal:  Curr Pulmonol Rep       Date:  2018-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.